SCHEMBL3523245

SCHEMBL3523245

Cc1nc(OCc2ccc(F)cc2F)cc(=O)n1CC1CCCO1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.47
HTR2C P28335 2/20 0.47
SLC6A4 P31645 2/20 0.47
GLP1R P43220 6/20 0.43
HSD17B10 Q99714 6/20 0.42
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
KCNH2 Q12809 1/20 0.41
ALDH1A1 P00352 6/20 0.41
CYP1A2 P05177 4/20 0.41
TSHR P16473 3/20 0.41
CYP2C19 P33261 3/20 0.41
HPGD P15428 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
GLA P06280 1/20 0.41
CYP2C9 P11712 1/20 0.41
KDM4E B2RXH2 4/20 0.41
CASP1 P29466 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4487933 0.82 HTR2A (0.46) HTR2AHTR2CSLC6A4HSD17B10ALDH1A1
SCHEMBL3520633 0.82 HTR2A (0.47) HTR2AHTR2CSLC6A4HSD17B10ALDH1A1
SCHEMBL3523048 0.77 MAPK14 (0.39)
SCHEMBL4487708 0.76 MAPK14 (0.59)
SCHEMBL3524686 0.73 MAPK14 (0.46) HSD17B10ALDH1A1CYP1A2TSHRCYP2C19
SCHEMBL3521142 0.73 PTGER1 (0.41) GLP1R
SCHEMBL3521145 0.73 PTGER1 (0.41) GLP1R
SCHEMBL13185698 0.73 MAPK14 (0.46)
SCHEMBL3520089 0.72 MAPK14 (0.51) GLP1R
SCHEMBL3527353 0.71 MAPK14 (0.57)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795271-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2010-09-14 US disclosed
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES PFIZER INC 2009-12-10 US disclosed
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES PHARMACIA CORPORATION (US) 2007-07-19 US disclosed
US-7183287-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2007-02-27 US disclosed
US-20040242608-A1 Substituted pyrimidinones PHARMACIA LLC 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 HTR2A 2026/4885HTR2C 1879/4885SLC6A4 3483/4885
US-20040242608-A1 Substituted pyrimidinones MAPK1, MAPK7, MAP3K8 HTR2A 2790/4885HTR2C 2139/4885SLC6A4 3395/4885
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 HTR2A 2026/4885HTR2C 1879/4885SLC6A4 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.